Unleashing the Potential of Tau Oligomer Inhibition

Oligomerix® Vision

To discover novel and differentiated small molecules and biomarkers focused on tau oligomer inhibition for the disease-modifying treatment of Alzheimer’s disease and other related neurodegenerative diseases

Upcoming Events

Alzheimer’s Association International Conference

Date, Time, & Room: Wednesday July 17, 9:30 AM-4:15 PM, South Hall GH
Poster Session: Developing Topics, Poster P4-18
Title: Linear dose-dependent inhibition of tau aggregation in vivo with small molecule
Speaker: James Moe, CEO & President, Oligomerix, Inc.
Venue: Los Angeles Convention Center

Neuroscience 2019

Date, Time, & Room: Tuesday October 22, 8:00 AM – 12:00 PM, Room S401
Session: Nanosymposium, Session Number 447
Session Title: Alzheimer’s Disease and Related Dementia: Therapeutic Strategies
Abstract Title: Selection of a small molecule tau oligomer inhibitor IND enabling studies
Venue: McCormick Place